Pharmanutra S.p.a. · MIL:PHN
Pharmanutra — H1 2022 Earnings Presentation
29 slides from Pharmanutra's earnings presentation, Sep 5, 2022
Slide 1: H1 2022 Financial Results
H1_2022 FINANCIAL RESULTS September 5th, 2022
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Group Presentation & Highlights 2022
GROUP PRESENTATION & HIGHLIGHTS 2022
Slide 4: Pharmanutra Group
4 PHARMANUTRA 2022 GROUP Research and development of bioimpedance medical devices and software for body composition analysis PharmaNutra holds 100% of 2010 Junia Pharma and Alesco and since end of July 2022 86,48% of Medical products and devices, OTC and dietary Akern’s share capital. supplements fo
Slide 5: Pharmanutra's Uniqueness
5 PHARMANUTRA’S UNIQUENESS Intellectual property protection 01 02 03 04 No player in the dietary supplements and medical devices industry has these 18 19 39 140 PROPRIETARY PATENTS BASED REGISTERED RESEARCH 4 STRONG PILLARS IN RAW MATERIALS ON PURE INNOVATION BRANDS STUDIES ONE SINGLE COMPANY PROPRI
Slide 6: Highlights H1 2022
6 HIGHLIGHTS H1 2022 ▪ Authorization by the European Union for the placing on the market of Lipocet® as Novel Food ▪ The patent on the use of Cetylated Fatty Acids (CFAs) has been granted in the United States ▪ Launch of the buy-back program in order to seize investment opportunities (34.719 own sha
Slide 7: Sustainability Report 2021
7 SUSTAINABILITY REPORT 2021 ▪ First step for the disclosure of non financial information on a yearly basis ; ▪ The Report focuses on the relevant aspects of the Group’s activities in terms of: - Governance - People - Innovation and products quality - Local communities - Suppliers - Environment ▪ Th
Slide 8: Economic and Financial Data
8 ECONOMIC AND FINANCIAL DATA
Slide 9: Highlights H1 2022
9 HIGHLIGHTS H1 - 2022 + 23% NET REVENUES € 39,7 M (+23% COMPARE TO H1 2021) ▪ 23% Increase in Net Sales Revenues EBITDA € 12,4 M ▪ 19.2% Domestic Sales increase + 21% (31,1% MARGIN ON REVENUES) ▪ 34.8% Foreign Sales increase ▪ 21% EBITDA Growth NET RESULT € 8,2 M + 25%* (20,6% MARGIN ON REVENUES) ▪
Slide 10: Net Revenues
10 NET REVENUES Revenues in the first half of 2022 accounted for € 39.7 million, recording a growth of 23% compared to the previous year. The increase was around 19% on the domestic market and around 35% on the foreign markets due to the concentration of orders in the first half of 2022.
Slide 11: Profit and Loss
11 PROFIT AND LOSS PROFIT AND LOSS (€/000) 30/06/2022 30/06/2021 REVENUES A) REVENUES 39.930 32.417 Consolidated revenues accounted for € 39,3 million with an increase of Net Revenues 39.711 32.273 23% compared to the same period of the previous year. The increase is Other revenues 219 144 due to th
Slide 12: Reclassified Consolidated Balance Sheet
12 RECLASSIFIED CONSOLIDATED BALANCE SHEET Amounts in €/000 30/06/2022 31/12/2021 ∆ 2022 vs 2021 Trade Receivables Trade receivables 20.994 16.673 4.321 The increase in trade receivables is due to higher revenues and Inventories 3.234 2.865 369 sales volumes. Trade Payables (10.419) (9.751) (668) Op
Slide 13: Consolidated Cash Flow
13 CONSOLIDATED CASH FLOW Cash Flow (€/000) 30/06/2022 30/06/2021 CASH FROM OPERATING ACTIVITIES Net Result 8.232 7.040 Change in operating working capital NON MONETARY EXPENSES Increase in trade receivables due to higher revenues and sales volumes. Amortization, depreciation and w.o. 594 560 Increa
Slide 14: Net Financial Position
14 NET FINANCIAL POSITION NFP The Net Financial Position at 30.06.2022 accounted for € 19,6 million. The decrease compared to 31.12.2021 is mainly due to the capital expenditures related to the construction of the new Headquarters (€ 5,5 million), to the purchases of treasury shares (€ 2,2 million)
Slide 15: Market
MARKET @PHARMANUTRA ~. ™ ™N SE™®™ ass
Slide 16: Trend IMS & OD
Trend IMS & OD IMS (Units) 250 230 Thousand 216 243 233 231 216244 210 203 199 199 192 197 197 190 185 170 150 130 huge21ago-21— set-27—ott-27— mow21—dit-21.—gen-22_—feb-22_— mar22_—opr22_— mag22_— Bur22_—hage22 IMS+OD (Units) 418 400 358 50 337 366 356 362 308 311 315 314 [175] 300 268 273 [rs] [13
Slide 17: Iron Supplements SiderAL Market Share in Italy
17 IRON SUPPLEMENTS SIDERAL® MARKET SHARE IN ITALY Excluding products that contain only lactoferrin Source IQVIA
Slide 18: Anti-Inflammatory Topical Cream Cetilar Market Share in Italy
18 ANTI-INFLAMMATORY TOPICAL CREAM CETILAR® MARKET SHARE IN ITALY Source IQVIA Source IQVIA
Slide 19: Apportal Compared to the Reference Markets
19 APPORTAL® COMPARED TO THE REFERENCE MARKETS
Slide 20: International Development
20 INTERNATIONAL DEVELOPMENT 5 new distribution contracts signed for Sideral® (Albania, Saudi Arabia, Denmark, Malta and Nigeria) and 1 new contract for Cetilar (Taiwan). COUNTRIES PARTNERS Contracts 68 45 Active Sales 59 38 On-going Registration 9 7 On-going Negotiation 7 7
Slide 21: Cross Border Ecommerce China
21 CINA CROSS BORDER ECOMMERCE CHINA ▪ Cross Border e-commerce is an increasingly significant component of China’s economy and its growing share of foreign trade; in 2021 the import-export market is worth 1.92 trillion yuan (about $284.5 billion); ▪ New store with the range of SiderAL® brand product
Slide 22: The Acquisition of Akern S.r.l.
THE ACQUISITION OF AKERN® S.R.L
Slide 23: Akern S.r.l.
23 AKERN® S.R.L. ▪ AKERN® is an Italian company founded in 1980, market leader in R&D of bioimpedance medical devices and software for body composition analysis; ▪ AKERN® technology delivers clinically significant results to support physicians and researchers in the assessment and treatment of acute
Slide 24: Akern Revenues and EBITDA
24 REVENUES 4.106k € EBITDA 1.160k € Ebitda margin on revenues 28,3% NET FINANCIAL POSITION NFP at 31/12/2021 847k €
Slide 25: The Strategic Synergies
25 THE STRATEGIC SYNERGIES ▪ Consolidation of Akern® presence on the Italian and International markets through the capillary network of PharmaNutra distributors; . ▪ Development of domestic and international sales; ▪ Creation of synergies to boost sales of PharmaNutra; ▪ Making a strategic contribut
Slide 26: Outlook 2022
OUTLOOK 2022 Q@PHARMANUTRA
Slide 27: Outlook 2022
OUTLOOK 2022 27 ▪ Product Marketing Strategy: strengthen SiderAL® leadership position in the oral iron market, increase Cetilar® market share and further develop of Apportal® and Ultramag® sales; ▪ International growth drivers: planning and implementing an entry strategy in the U.S. market and enlar
Slide 28: New Headquarter Site
28 NEW HEADQUARTER SITE The new industrial facility will enable PharmaNutra Group to position itself as a more relevant and innovative entity in the chemical&pharmaceutical industry. New site will allow full control of sucrosomial elements production and an even stronger R&D focus. The new offices w
Slide 29: Pharmanutra
MPHARMANUTRA